[
  {
    "ts": null,
    "headline": "Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says",
    "summary": "Veeva Systems (VEEV) is likely to post fiscal Q2 results that come in line to better and maintain it",
    "url": "https://finnhub.io/api/news?id=c8f3dafce4ea1eeebf6d97b2299baef6ecacd9beb6e91a65f5a99c83ba350dee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755716394,
      "headline": "Veeva Systems Q2 Results Likely In-Line to Better, Maintain H2 Outlook, Truist Says",
      "id": 136449057,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Veeva Systems (VEEV) is likely to post fiscal Q2 results that come in line to better and maintain it",
      "url": "https://finnhub.io/api/news?id=c8f3dafce4ea1eeebf6d97b2299baef6ecacd9beb6e91a65f5a99c83ba350dee"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer battles another Paxlovid lawsuit from Enanta",
    "summary": "Pfizer says it is “confident” in the intellectual property for its billion-dollar Covid-19 pill Paxlovid.",
    "url": "https://finnhub.io/api/news?id=c34d1de9a1638d8341e807efca381201da1b25ec1cee598b7c6f7bfdaa952ebd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755708817,
      "headline": "Pfizer battles another Paxlovid lawsuit from Enanta",
      "id": 136449058,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer says it is “confident” in the intellectual property for its billion-dollar Covid-19 pill Paxlovid.",
      "url": "https://finnhub.io/api/news?id=c34d1de9a1638d8341e807efca381201da1b25ec1cee598b7c6f7bfdaa952ebd"
    }
  },
  {
    "ts": null,
    "headline": "Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.",
    "summary": "Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.",
    "url": "https://finnhub.io/api/news?id=0af53cec36039541f9708e2eac7ef45af4cdb44d708cd5633c7e6343a6257c0f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755706980,
      "headline": "Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.",
      "id": 136455593,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Covid-19 Vaccine Guidelines Are Changing. What We Know About Who Can Get a Shot.",
      "url": "https://finnhub.io/api/news?id=0af53cec36039541f9708e2eac7ef45af4cdb44d708cd5633c7e6343a6257c0f"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500: Sick Puppies Dominate, But Here's A Trio Of A-List Stocks To Consider",
    "summary": "Discover why the S&P 500 conceals stock weaknesses & explore 3 healthcare picks from a data-driven analysis.",
    "url": "https://finnhub.io/api/news?id=20d39b5f35afe6cce3e909d2349678795903093ada48bbb6a9061a93ae5230c7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755701752,
      "headline": "S&P 500: Sick Puppies Dominate, But Here's A Trio Of A-List Stocks To Consider",
      "id": 136439471,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1366605148/image_1366605148.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why the S&P 500 conceals stock weaknesses & explore 3 healthcare picks from a data-driven analysis.",
      "url": "https://finnhub.io/api/news?id=20d39b5f35afe6cce3e909d2349678795903093ada48bbb6a9061a93ae5230c7"
    }
  },
  {
    "ts": null,
    "headline": "Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union",
    "summary": "WATERTOWN, Mass., August 20, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’265",
    "url": "https://finnhub.io/api/news?id=f97faf149ff51f2f9de766a926003f8939b46dd0461cb3cb11fe58101873da0e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755687600,
      "headline": "Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union",
      "id": 136437648,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "WATERTOWN, Mass., August 20, 2025--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the ’265",
      "url": "https://finnhub.io/api/news?id=f97faf149ff51f2f9de766a926003f8939b46dd0461cb3cb11fe58101873da0e"
    }
  },
  {
    "ts": null,
    "headline": "Enata Sues Pfizer in European Union Over Paxlovid Covid-19 Drug -- Update",
    "summary": "Enata Sues Pfizer in European Union Over Paxlovid Covid-19 Drug -- Update",
    "url": "https://finnhub.io/api/news?id=b401d948d1f82985a104e8fb2bfbb784f8c8a602a4a49ef509f67e1943ca651d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755681780,
      "headline": "Enata Sues Pfizer in European Union Over Paxlovid Covid-19 Drug -- Update",
      "id": 136455594,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Enata Sues Pfizer in European Union Over Paxlovid Covid-19 Drug -- Update",
      "url": "https://finnhub.io/api/news?id=b401d948d1f82985a104e8fb2bfbb784f8c8a602a4a49ef509f67e1943ca651d"
    }
  },
  {
    "ts": null,
    "headline": "My Top Dividend-Paying, Deep-Value Stock to Buy in August",
    "summary": "You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock.",
    "url": "https://finnhub.io/api/news?id=d3ee851073d969dd3f31c153e8fb493257c6a8099a9c15ebbd3c02f13d319dc5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755679860,
      "headline": "My Top Dividend-Paying, Deep-Value Stock to Buy in August",
      "id": 136437649,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "You won't find many stocks with a juicier dividend and more attractive valuation than this big pharma stock.",
      "url": "https://finnhub.io/api/news?id=d3ee851073d969dd3f31c153e8fb493257c6a8099a9c15ebbd3c02f13d319dc5"
    }
  },
  {
    "ts": null,
    "headline": "Enata Sues Pfizer Over Paxlovid Covid-19 Drug",
    "summary": "Enata Sues Pfizer Over Paxlovid Covid-19 Drug",
    "url": "https://finnhub.io/api/news?id=bc164b93d0bc0e5004387ca5e43984b3ce156ba8d40aad307a47b5fb34d87386",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755677280,
      "headline": "Enata Sues Pfizer Over Paxlovid Covid-19 Drug",
      "id": 136455595,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Enata Sues Pfizer Over Paxlovid Covid-19 Drug",
      "url": "https://finnhub.io/api/news?id=bc164b93d0bc0e5004387ca5e43984b3ce156ba8d40aad307a47b5fb34d87386"
    }
  },
  {
    "ts": null,
    "headline": "2 S&P 500 Stocks to Own for Decades and 1 We Ignore",
    "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
    "url": "https://finnhub.io/api/news?id=e9dedffdb3ea0710de12dd6a000cd91acf17d3e949efbea4fa4ab31853269f1b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755664355,
      "headline": "2 S&P 500 Stocks to Own for Decades and 1 We Ignore",
      "id": 136437581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.",
      "url": "https://finnhub.io/api/news?id=e9dedffdb3ea0710de12dd6a000cd91acf17d3e949efbea4fa4ab31853269f1b"
    }
  },
  {
    "ts": null,
    "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
    "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
    "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755663369,
      "headline": "Pharmaceuticals Industry Analysis:  Eli Lilly Tops My Tier Two",
      "id": 136435370,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1291269124/image_1291269124.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Tier-two pharma picks show solid fundamentals, but Eli Lilly (LLY) stock stands out for its growth potential. Read here for an analysis.",
      "url": "https://finnhub.io/api/news?id=c3907d374789a13bcc0a4f263b16cfc191ed507efec252bde9661f419a70bf5a"
    }
  }
]